000			01552 a2200421 4500
005			20250515094802.0
264		0	_c20080516
008			200805s 0 0 ger d
022			_a0020-9554
024	7		_a10.1007/s00108-007-1979-6 _2doi
040			_aNLM _beng _cNLM
100	1		_aBuerke, M
245	0	0	_a[New pharmacological treatment approaches to cardiogenic shock]. _h[electronic resource]
260			_bDer Internist _cDec 2007
300			_a1442-9 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xadverse effects
650	0	4	_aCardiotonic Agents _xadverse effects
650	0	4	_aCatecholamines _xadverse effects
650	0	4	_aComplement C5 _xantagonists & inhibitors
650	0	4	_aComplement Inactivating Agents _xadverse effects
650	0	4	_aHumans
650	0	4	_aHydrazones _xadverse effects
650	0	4	_aIntra-Aortic Balloon Pumping
650	0	4	_aMyocardial Infarction _xcomplications
650	0	4	_aMyocardial Revascularization
650	0	4	_aNitric Oxide Synthase _xantagonists & inhibitors
650	0	4	_aPyridazines _xadverse effects
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aShock, Cardiogenic _xdrug therapy
650	0	4	_aSimendan
650	0	4	_aSurvival Rate
650	0	4	_aVasopressins _xadverse effects
700	1		_aRuss, M
700	1		_aWerdan, K
773	0		_tDer Internist _gvol. 48 _gno. 12 _gp. 1442-9
856	4	0	_uhttps://doi.org/10.1007/s00108-007-1979-6 _zAvailable from publisher's website
999			_c17549764 _d17549764